Résumé
Live attenuated vaccines (LAVs) whose virulence would be controlled at the tissue level could be a crucial tool to effectively fight intracellular bacterial pathogens, because they would optimize the induction of protective immune memory while avoiding the long-term persistence of vaccine strains in the host. Rational development of these new LAVs implies developing an exhaustive map of the bacterial virulence genes according to the host organs implicated. We report here the use of transposon sequencing to compare the bacterial genes involved in the multiplication of Brucella melitensis, a major causative agent of brucellosis, in the lungs and spleens of C57BL/6 infected mice. We found 257 and 135 genes predicted to be essential for B. melitensis multiplication in the spleen and lung, respectively, with 87 genes common to both organs. We selected genes whose deletion is predicted to produce moderate or severe attenuation in the spleen, the main known reservoir of Brucella, and compared deletion mutants for these genes for their ability to protect mice against challenge with a virulent strain of B. melitensis. The protective efficacy of a deletion mutant for the plsC gene, implicated in phospholipid biosynthesis, is similar to that of the reference Rev.1 vaccine but with a shorter persistence in the spleen. Our results demonstrate that B. melitensis faces different selective pressures depending on the organ and underscore the effectiveness of functional genome mapping for the design of new safer LAV candidates.
langue originale | Anglais |
---|---|
Numéro d'article | e1012459 |
Pages (de - à) | e1012459 |
journal | Plos Pathogens |
Volume | 20 |
Numéro de publication | 8 August |
Les DOIs | |
Etat de la publication | Publié - 1 août 2024 |
Empreinte digitale
Examiner les sujets de recherche de « Genome-wide analysis of Brucella melitensis growth in spleen of infected mice allows rational selection of new vaccine candidates ». Ensemble, ils forment une empreinte digitale unique.Équipement
-
Laboratoire de sécurité biologique au niveau 3 (BL3)
De Bolle, X. (!!Manager)
Plateforme technologique Laboratoire de securite biologique au niveau 3Equipement/installations: Plateforme technolgique